echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Urinary System > Research frontiers Safety outcomes of the TALAPRO-1 study

    Research frontiers Safety outcomes of the TALAPRO-1 study

    • Last Update: 2022-11-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com



    Guide

     The TALAPRO-1 study (NCT03148795) is an international phase II trial evaluating the efficacy and tolerability of talazoparib monotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC) and DDR-HRR gene mutations.


    Research background


    Talazoparib is a novel polyADP ribose polymerase (PARP) inhibitor, and this article analyzes the safety data of Talazoparib in mCRPC patients in detail, which may provide some insights
    for clinicians to manage adverse events (AEs) and conduct clinical trials of Talazoparib in combination with other anticancer drugs.


    Study design


    Patients were given oral Talazoparib 1.
    0 mg/day (0.
    75 mg/day in patients with moderate renal impairment) until imaging progression, intolerable toxicity, dropout, or death
    .
    Safety outcomes included incidence, severity, time of occurrence, duration, overlap of adverse events (TEAEs) occurring during treatment (simultaneous experience of two AEs≥1 day), dose adjustment/discontinuation due to AEs, and significant changes
    in laboratory indicators and vital signs.


    Research results


    Among the safety population (N = 127, median age 69 years), 95.
    3% (121/127) of patients experienced TEAEs
    .
    The most common TEAEs were anaemia (62/127; 48.
    8%), nausea and vomiting (42/127; 33.
    1%), loss of appetite (36/127; 28.
    3%), and fatigue (30/127; 23.
    6%)
    .
    Non-hematology TEAEs are usually grade
    1 and 2.
    No grade 5 TEAEs or treatment-related deaths
    occurred.

     

    Fig.
    1 Levels of TEAEs occurring in the safety population (A: Comprehensive; B: Hematology TEAEs; C: Non-hematology TEAEs)


    Hematology TEAEs usually occur in the 4-5 months of treatment start, the median duration of grade 3/4 hematology TEAEs such as anemia, neutropenia, and thrombocytopenia is usually 7-12 days, and patients do not experience grade 4 anemia or neutropenia events
    .
    BRCA status and source of mutations in the DDR-HRR gene were not significantly associated
    with patient safety outcomes.
    The median duration of treatment for patients treated with Talazoparib was 6.
    1 (range: 0.
    4-24.
    9) months, independent
    of the incidence of anaemia.
    Of the 15 (15/127; 11.
    8%) patients with permanent treatment interruption due to AEs, only 3 were discontinued due to hematology TEAEs, of which 2 (2/127; 1.
    6%) had thrombocytopenia and 1 (1/127; 0.
    8%) leukopenia
    .


    Conclusion of the study


    In the TALAPRO-1 study, no new safety signals
    were observed with Talazoparib monotherapy.
    Clinicians can address common TEAEs associated with Talazoparib with dose titrations and supportive care, and the controlled safety profile and good antitumor activity support future Phase III trials to further evaluate the use
    of Talazoparib in mCRPC.


    References:

    Mehra N, Fizazi K, de Bono JS, et al.
    Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses.
    Oncologist.
    2022 Oct 1; 27(10):e783-e795.

    Editor: Wang Mumu Review: LR Execution: Wang Mumu


    This platform aims to deliver more medical information
    to healthcare professionals.
    The content published on this platform cannot replace professional medical guidance in any way, nor should it be regarded as diagnosis and treatment advice
    .
    If such information is used for purposes other than understanding medical information, this platform does not assume relevant responsibilities
    .
    The content published by this platform does not mean that it agrees with its description and views
    .
    If copyright issues are involved, please contact us and we will deal with it
    as soon as possible.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.